Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy

Laith N AL-Eitan,1,2 Ayah Y Almasri,1 Sahar O Al-Habahbeh1 1Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan Purpose: Thi...

Full description

Bibliographic Details
Main Authors: AL-Eitan LN, Almasri AY, Al-Habahbeh SO
Format: Article
Language:English
Published: Dove Medical Press 2019-01-01
Series:Pharmacogenomics and Personalized Medicine
Subjects:
Online Access:https://www.dovepress.com/effects-of-coagulation-factor-vii-polymorphisms-on-warfarin-sensitivit-peer-reviewed-article-PGPM
_version_ 1817995843583606784
author AL-Eitan LN
Almasri AY
Al-Habahbeh SO
author_facet AL-Eitan LN
Almasri AY
Al-Habahbeh SO
author_sort AL-Eitan LN
collection DOAJ
description Laith N AL-Eitan,1,2 Ayah Y Almasri,1 Sahar O Al-Habahbeh1 1Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan Purpose: This study aims to investigate the relationships between genetic polymorphisms of the coagulation factor VII (FVII) gene and warfarin responsiveness and sensitivity. Patients and methods: The study population consisted of 417 subjects (207 Jordanian cardiovascular patients and 210 healthy individuals). Cardiovascular patients were classified into two groups: those sensitive to warfarin dosage (sensitive, moderate, and resistant) and those responsive to warfarin based on International Normalized Ratios (INRs; poor, good, and extensive responders). The HVR4 polymorphism of the FVII gene was genotyped. Results: Our results showed that there are significant differences between patients and controls according to both genotypic and allelic frequencies (P<0.0001) in the genetic susceptibility study. Moreover, the pharmacogenetics study reported that HVR4 had no association with warfarin sensitivity or responsiveness during the initiation and maintenance phases of therapy, the only significant differences were in the INR outcome measured during the maintenance phase of therapy (P=0.012). Conclusion: Our data suggests lacking of association between the HVR4 polymorphism in the FVII gene and warfarin sensitivity and responsiveness during the initiation and maintenance phases of therapy. It is possible that these patients carry additional mutations in genes involved in the coagulation pathway. Keywords: HVR4 polymorphism, cardiovascular disease, pharmacogenetics study
first_indexed 2024-04-14T02:13:07Z
format Article
id doaj.art-589dca8223bb475284739d6b5d2562e0
institution Directory Open Access Journal
issn 1178-7066
language English
last_indexed 2024-04-14T02:13:07Z
publishDate 2019-01-01
publisher Dove Medical Press
record_format Article
series Pharmacogenomics and Personalized Medicine
spelling doaj.art-589dca8223bb475284739d6b5d2562e02022-12-22T02:18:20ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662019-01-01Volume 121843543Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapyAL-Eitan LNAlmasri AYAl-Habahbeh SOLaith N AL-Eitan,1,2 Ayah Y Almasri,1 Sahar O Al-Habahbeh1 1Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan Purpose: This study aims to investigate the relationships between genetic polymorphisms of the coagulation factor VII (FVII) gene and warfarin responsiveness and sensitivity. Patients and methods: The study population consisted of 417 subjects (207 Jordanian cardiovascular patients and 210 healthy individuals). Cardiovascular patients were classified into two groups: those sensitive to warfarin dosage (sensitive, moderate, and resistant) and those responsive to warfarin based on International Normalized Ratios (INRs; poor, good, and extensive responders). The HVR4 polymorphism of the FVII gene was genotyped. Results: Our results showed that there are significant differences between patients and controls according to both genotypic and allelic frequencies (P<0.0001) in the genetic susceptibility study. Moreover, the pharmacogenetics study reported that HVR4 had no association with warfarin sensitivity or responsiveness during the initiation and maintenance phases of therapy, the only significant differences were in the INR outcome measured during the maintenance phase of therapy (P=0.012). Conclusion: Our data suggests lacking of association between the HVR4 polymorphism in the FVII gene and warfarin sensitivity and responsiveness during the initiation and maintenance phases of therapy. It is possible that these patients carry additional mutations in genes involved in the coagulation pathway. Keywords: HVR4 polymorphism, cardiovascular disease, pharmacogenetics studyhttps://www.dovepress.com/effects-of-coagulation-factor-vii-polymorphisms-on-warfarin-sensitivit-peer-reviewed-article-PGPMFactor VII polymorphismcardiovascular diseasepharmacogenetics study
spellingShingle AL-Eitan LN
Almasri AY
Al-Habahbeh SO
Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
Pharmacogenomics and Personalized Medicine
Factor VII polymorphism
cardiovascular disease
pharmacogenetics study
title Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
title_full Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
title_fullStr Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
title_full_unstemmed Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
title_short Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
title_sort effects of coagulation factor vii polymorphisms on warfarin sensitivity and responsiveness in jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
topic Factor VII polymorphism
cardiovascular disease
pharmacogenetics study
url https://www.dovepress.com/effects-of-coagulation-factor-vii-polymorphisms-on-warfarin-sensitivit-peer-reviewed-article-PGPM
work_keys_str_mv AT aleitanln effectsofcoagulationfactorviipolymorphismsonwarfarinsensitivityandresponsivenessinjordaniancardiovascularpatientsduringtheinitiationandmaintenancephasesofwarfarintherapy
AT almasriay effectsofcoagulationfactorviipolymorphismsonwarfarinsensitivityandresponsivenessinjordaniancardiovascularpatientsduringtheinitiationandmaintenancephasesofwarfarintherapy
AT alhabahbehso effectsofcoagulationfactorviipolymorphismsonwarfarinsensitivityandresponsivenessinjordaniancardiovascularpatientsduringtheinitiationandmaintenancephasesofwarfarintherapy